


CASE REPORT

Open Access



Collision of ductal adenocarcinoma and neuroendocrine tumor of the pancreas: a case report and review of the literature

Simone Serafini¹, Gianfranco Da Dalt¹, Gioia Pozza¹, Stella Blandamura², Michele Valmasoni¹, Stefano Merigliano¹ and Cosimo Sperti^{1*} 

Abstract

Background: Simultaneous occurrence of exocrine and neuroendocrine tumors of the pancreas is very infrequent. We report a patient with an endocrine tumor in the pancreatic-duodenal area and extensive exocrine carcinoma involving the whole pancreas.

Case presentation: A 69-year-old woman was hospitalized in May 2016 for epigastric pain and weight loss. Her past medical history revealed an undefined main pancreatic duct dilation that was subsequently confirmed at CT scan (23 mm) and endoscopic ultrasound. There was no evidence of pancreatic masses, but the cephalic portion of the main pancreatic duct presented hypoechoic nodules. A diagnosis of the main-duct intraductal papillary mucinous neoplasm was made, and the patient underwent total pancreatectomy. Pathological examination showed a collision tumor constituted by a ductal adenocarcinoma involving the whole pancreas and a neuroendocrine tumor located in the duodenal peripancreatic wall and the head of the pancreas. There was one peripancreatic lymph node metastasis from the ductal adenocarcinoma and eight node metastases from the neuroendocrine tumor. These findings suggested a diagnosis of collision of neuroendocrine and ductal adenocarcinomas of the pancreas. The postoperative course was uneventful.

Conclusions: The coexistence of pancreatic endocrine and exocrine tumors is very uncommon. When present, problems in differential diagnosis may arise between mixed exocrine-endocrine carcinoma or the collision of separate tumors.

Keywords: Collision tumor, GIST, Intraductal papillary mucinous tumor, Neuroendocrine tumor, Pancreatic cancer

Background

Simultaneous occurrence of a pancreatic exocrine and endocrine tumor (neuroendocrine tumor (NET)) is very infrequent. In large series studies, the incidence of combined neoplasms ranged only from 0.06 to 0.2% of all pancreatic tumors [1, 2]. Collision cancers are defined as tumors located in the same organ or anatomic site. According to the World Health Organization (WHO) histological classification, collision tumors include at least two different malignant components, without mixed or transitional area [3]. In this study, we report a patient with a

collision pancreatic tumor constituted by a pancreatic ductal adenocarcinoma (PDAC) and NET associated with a jejunal gastrointestinal stromal tumor (GIST). A review of the English literature was performed searching PubMed (MEDLINE) using “pancreatic neoplasms,” “pancreatic cancer,” “neuroendocrine tumor,” and “pancreatic collision tumor” as keywords. The related article function was used, and all abstracts, studies, and citations obtained were reviewed. To our knowledge, this is the first case of an extensive PDAC that collided with a NET.

Case presentation

A 68-year-old Caucasian woman was admitted in May 2016 for the examination of a suspected intraductal papillary mucinous neoplasm (IPMN). Her previous medical

* Correspondence: csperti@libero.it

¹Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, via Giustiniani 2, 35128 Padua, Italy
Full list of author information is available at the end of the article

history included breast cancer, diabetes mellitus, hypertension, hypercholesterolemia, and multiple congenital skeletal dysplasia. She presented with weight loss, epigastric pain, and fatigue. Laboratory examination revealed high carbohydrate antigen 19-9 (Ca 19-9) serum levels (139.9 U/mL; normal value <37 U/mL). Triple-phase computed tomography (CT) of the abdomen detected a dilated main duct (diameter of 23 mm from the head to the tail) without solid lesions (Fig. 1). Endoscopic ultrasound (EUS) confirmed main duct dilatation >20 mm, with mural hypoechoic nodules (Fig. 2). Malignant main-duct IPMN was suggested, and the patient underwent surgery. At laparotomy, neither liver metastasis nor peritoneal seeding were found. A solid 26-mm lesion in the jejunal wall was incidentally detected. So, total pancreatectomy and excision of the jejunal lesion were performed. The postoperative period was uneventful.

Macroscopic examination of the resected specimen showed a dilated main pancreatic duct (diameter of 20 mm for a length of 80 mm); an irregular, not well-defined mass (50 mm in longest diameter) in the body-tail of the pancreas; and a solid lesion in the jejunum.

Microscopic sections showed a collision pancreatic tumor constituted by a ductal adenocarcinoma, including pancreatic intraepithelial neoplasia (PanIN), and a G1 NET, in the duodenal peripancreatic wall and the head of the pancreas (Fig. 3). The PDAC collided with the NET without mixing: the NET was localized in the periduodenal portion of the head of the pancreas reaching also the duodenal wall nearby Vater's ampulla, while the exocrine component of the tumor involved the remaining pancreas, from the head to the tail. Lympho-vascular invasion and perineural spreading were also detected. Thirty-nine regional lymph nodes were examined in the resected specimen with one node metastasis (peripancreatic node) from the PDAC and eight node




Fig. 2 Endoscopic ultrasound showing a marked dilation of the pancreatic main duct

metastases from the NET (seven peripancreatic nodes and one para-aortic node). The ductal differentiation was of conventional type, characterized by medium-sized glandular structures of variable shapes, embedded in desmoplastic stroma with foci of poor glandular differentiation found in the peripancreatic tissue. The neoplastic glands infiltrated the underlying duodenum. The endocrine component grew up in the head of the pancreas and in the duodenal wall reaching the submucosa, with signs of endo-lymphatic invasion. At immunohistochemistry analysis, endocrine cells were synaptophysin+ (Fig. 4), chromogranin A+ (Fig. 5), NSE +, and somatostatin+ (weakly) and showed a mitotic index of 1–2 mitoses × 10 HPE, a Ki-67 proliferation index of 2%, and



Fig. 1 Abdominal CT scan showing the dilation of the pancreatic main duct




Fig. 3 Pancreatic slide view of the collision tumor. The morphological differences between the two types of tumors are remarkable: NET on the upper left side and PDAC on the right




Fig. 4 Immunohistochemical synaptophysin slide showing positive neuroendocrine cells

frequent psammoma bodies. Reactions for gastrin, serotonin, insulin, glucagon, calcitonin, and pancreatic polypeptide were negative. Ductal dysplasia and carcinoma in situ, characterized by irregular epithelial budding and bridging, small papillae, lack of fibro-vascular stalks, and severe nuclear abnormalities, were detected in the pancreas and in the pancreatic main duct. Pathological examination of the jejunal lesion showed a fusiform type GIST, CD117+ and CD34+, and wildtype for *c-KIT/PDGFR*A.

After surgery, the patient refused gemcitabine-based adjuvant treatment. Currently, the patient has no signs of relapse 8 months after surgery.

Discussion

We report the first case of a collision pancreatic tumor constituted by a PDAC, without features of IPMNs, and NET, associated with an incidental jejunal GIST. Pre-operative work-up was consistent with malignant main-




Fig. 5 Immunohistochemical chromogranin A slide showing positive neuroendocrine cells

duct IPMN, due to the dilation of the pancreatic main duct (more than 2 cm), high serum Ca 19-9 levels, and patient's symptoms. Surprisingly, pathological examination showed an extensive adenocarcinoma that collided with a neuroendocrine tumor involving the duodenum and the head of the pancreas, with metastasis at the peripancreatic and para-aortic nodes.

Collision tumors of the pancreas are rare; sporadic cases of concomitant or collision tumors constituted by IPMNs and NET [4–7], solid pseudopapillary neoplasm and NET [8], and cancer of the bile duct and pancreas [9] have been previously reported, but clinicopathological features and prognosis of these tumors are substantially unclear. The incidence of concomitant IPMNs and NETs has been reported in a range from 2.6 to 4.6%, suggesting a non-random association [10–12]. In most cases, the coexistence of both tumors was an incidental discovery after the examination of the surgical specimen. Two cases of a concomitant IPMN and a pancreatic NET diagnosed before surgery have also been reported [13]. In 2013, Ishida et al. [7] described a case of simultaneous IPMN and NET in the pancreas and collected 15 previously reported cases. Half of the patients were symptomatic (mainly abdominal pain), only one patient presented with hormone-secreting tumor, three patients had metastases from a NET, and one patient died due to a metastatic NET. The origin of the neoplastic population (common progenitor cell or random association) has not been explained. Many authors suggested that these tumors may arise from common precursor stem cells [10, 14–16] as showed by a recent molecular lineage study [17]. Others hypothesized that the carcinogenesis of collision cancer may lead to alteration of local immunodefence after the development of one tumor or to the effect of a carcinogenic agent able to affect different targets simultaneously [5]. Prognosis of collision malignant tumors is still unclear. In 2010, the largest experience of collision cancers based on ten heterogeneous cases of pancreatic and periampullary cancers was reported [5]. In this series, most collision cancers were IPMNs coexisting with other malignancies (PDAC, NET, lower end of common bile duct, and duodenal ampullary carcinoma) and showed poor prognosis with a median survival time of only 10 months.

Moriyoshi et al. [4] reported an interesting case of a collision pancreatic tumor constituted by extensive PanIN, coexisting with IPMNs with focal invasion and multiple NETs in a patient affected by multiple endocrine neoplasia type 1. No lymph nodes metastases were found; follow-up of the patient is not reported. Most of NETs concomitant with exocrine neoplasms are non-functioning tumors, but two cases of IPMNs and endocrine syndrome from nesidioblastosis (hypoglycemia) and vipoma (watery diarrhea), respectively, have been reported [18, 19].

In our case, the presence of psammoma bodies could suggest a somatostatin-producing NET; however, immunohistochemistry examination showed only a weak positivity for somatostatin and negativity for gastrin, serotonin, and pancreatic hormones. Moreover, the coexistence of a NET and a GIST suggests a possible type 1 neurofibromatosis, but the patient did not have clinical manifestations (such as cutaneous and ocular) or familial history of the disease.

Differential diagnosis between mixed exocrine-endocrine and collision tumors may arise. However, in the mixed type, the exocrine-endocrine cells are closely combined [20] while the collision type shows separate endocrine and exocrine components without an intermixed central zone [3], as in our case.

Survival of patients with an extensive adenocarcinoma and a malignant NET of the pancreas is obviously unknown. Our patient refused adjuvant therapy, but she is still alive and disease-free 8 months after surgery.

Conclusions

In conclusion, we report a new case of adenocarcinoma coexisting with a metastatic NET of the pancreas, misinterpreted as a malignant IPMN. Intraoperative detection of a jejunal GIST also occurred. Based on our case and review of the literature, collision pancreatic cancer is a very uncommon tumor composed at least of two different malignant components. Pathogenesis of this rare entity is substantially unclear, and problems in differential diagnosis may arise between mixed exocrine-endocrine carcinoma or the collision of two distinct tumors. Preoperative diagnosis is difficult because of the lack of specific symptoms and radiological features. Radical resection is still the treatment of choice for resectable tumors, but the prognosis appears unpredictable.

Abbreviations

GIST: Gastrointestinal stromal tumor; IPMN: Intraductal papillary mucinous neoplasm; NET: Neuroendocrine tumor; PDAC: Pancreatic ductal adenocarcinoma; WHO: World Health Organization.

Acknowledgements

Not applicable

Funding

None

Availability of data and materials

Not applicable

Authors' contributions

SS and CS conceived the study, carried out the literature search, and drafted the manuscript. GDD and GP helped in the management of the patient. SB carried out the pathologic diagnosis and immunoassays. MV and SM made critical revision and supervision of the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying image. A copy of the written consent is available for review by the Editor-in-Chief of this Journal.

Ethics approval and consent to participate

Not applicable. As per the University of Padua Institutional Review Board, case reports do not need ethical approval and no patient identifiers appear in the report. Therefore, ethical approval was not required for this case report; however, written informed consent was obtained from the patient involved in this study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua, via Giustiniani 2, 35128 Padua, Italy. ²Department of Pathology, University of Padua, Padua, Italy.

Received: 27 October 2016 Accepted: 23 April 2017

Published online: 02 May 2017

References

- Cubilla AL, Fitzgerald PJ. Cancer of the exocrine pancreas: the pathologic aspects. *CA Cancer J Clin.* 1985;35(1):2–18.
- Tanaka M. Pancreatic cancer registry report 2007. *Suizo.* 2007;22:e26–28.
- Kloppel G, Hruban RH, Longnecker DS, Adler G, Kern SE, Partanen TJ. Ductal adenocarcinoma of the pancreas. In Pathology and genetics of tumours of digestive system. Hamilton SR, Aaltonen LA Edithors. World Health Organization Classification of Tumours. Lyon, International Agency for Research on Cancer. 2000:224.
- Moriyoshi K, Minamiguchi S, Miyagawa-Hayashino A, Fujimoto M, Kawaguchi M, Haga H. Collision of extensive exocrine and neuroendocrine neoplasms in multiple endocrine neoplasia type 1 revealed by cytogenetic analysis of loss of heterozygosity: a case report. *Pathol Int.* 2013;63(9):469–75.
- Niu GM, Jin DY, Ji Y, Hou J, Wang DS, Lou WH. Survival analysis of pancreatic and periampullary collision cancers. *J Dig Dis.* 2010;11(4):231–36.
- Tewari N, Zaitoun AM, Lindsay D, Abbas A, Ilyas M, Lobo DN. Three cases of concomitant intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumour. *JOP.* 2013;14(4):423–27.
- Ishida M, Shiomi H, Naka S, Tani T, Okabe H. Concomitant intraductal papillary mucinous neoplasm and neuroendocrine tumor of the pancreas. *Oncol Lett.* 2013;5:63–7.
- Yan SX, Adair CF, Balani J, Mansour JC, Gokaslan ST. Solid pseudopapillary neoplasm collided with a well-differentiated pancreatic endocrine neoplasm in an adult man. *Am J Clin Pathol.* 2015;143(2):283–87.
- Izumi H, Furukawa D, Yazawa N, Masuoka Y, Yamada M, Tobita K, Kawashima Y, Ogawa M, Kawaguchi Y, Hirabayashi K, Nakagohri T. A case of collision tumor composed of cancers of the bile duct and pancreas. *Surg Case Rep.* 2015;1(1):40.
- Marrache F, Cazals-Hatem D, Kianmanesh R, Palazzo L, Couvelard A, O'Toole D, Maire F, Hammel P, Levy P, Sauvanet A, Ruszniewski P. Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? *Pancreas.* 2005;31(1):79–83.
- Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK. Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. *Pancreatol.* 2006;6(6):520–26.
- Gill KRS, Scimeca D, Stauffer J, Krishna J, Woodward TA, Jamil LH, Wallace MB, Nguyen JH, Raimondo M. Pancreatic neuroendocrine tumors among patients with intraductal papillary mucinous neoplasms: real incidence or just a coincidence? *JOP.* 2009;10(5):515–17.
- Larghi A, Stobinski M, Galasso D, Lecca PG, Costamagna G. Concomitant intraductal papillary mucinous neoplasm and pancreatic endocrine tumour: report of two cases and review of the literature. *Dig Liver Dis.* 2009;41(10):759–61.
- Morikane K, Kimura W, Inoue S, Muto T. A small glucagonoma of the pancreas with evident ductular and tubular structures. *J Gastroenterol.* 1997;32(4):562–5.

15. Stukavec J, Jirasek T, Mandys V, et al. Poorly differentiated endocrine carcinoma and intraductal papillary-mucinous neoplasm of the pancreas: description of an unusual case. *Pathol Res Pract*. 2007;203(12):879–8.
16. Chatelain D, Parc Y, Christin-Maitre S, Parc R, Flejou JF. Mixed ductal-pancreatic polypeptide-cell carcinoma of the pancreas. *Histopathology*. 2002;41(2):122–26.
17. Bardeesy N, De Pinho RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer*. 2002;2(12):897–909.
18. Zhao X, Stabile BE, Mo J, Wang J, French SW. Nesidioblastosis coexisting with islet cell tumor and intraductal papillary mucinous hyperplasia. *Arch Pathol Lab Med*. 2001;125:1344–7.
19. Ishizu S, Setoyama T, Ueo T, Ueda Y, Kodama Y, Ida H, Kawaguchi Y, Yoshizawa A, Chiba T, Miyamoto S. Concomitant case of intraductal papillary mucinous neoplasm of the pancreas and functioning pancreatic neuroendocrine tumor (vasoactive intestinal polypeptide-producing tumor): first report. *Pancreas*. 2016;45(6):e24–5.
20. Chang SM, Yan ST, Wei CK, Lin CW, Tseng CE. Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas. *World J Gastroenterol*. 2010;16(21):2692–97.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

